Story
Sanofi to Pay Regeneron Up to $8 Billion in Expanded Drug Development Pact

Sanofi SA will pay its long-term partner Regeneron $1 billion upfront to expand their collaboration on four new long-acting medicines for inflammatory diseases, a deal with a potential total value of up to $8 billion. The agreement aims to build the French drugmaker's pipeline beyond its blockbuster treatment, Dupixent, which the two companies also co-developed.
Deal Structure and Financials
Under the terms announced by the companies on Thursday, Sanofi's initial payment will be followed by up to $7 billion in additional milestone payments. These future payments are contingent on the new drugs achieving specific development, regulatory, and sales targets.
The partnership calls for the two companies to jointly develop and commercialize four new antibody-based medicines. Development and sales costs, as well as potential profits, will be split equally worldwide. Regeneron is set to lead the development of the medicines, while Sanofi will be responsible for global sales.
Strategic Rationale and Pipeline
The collaboration gives Sanofi access to promising new treatments as it seeks to diversify its revenue streams beyond Dupixent. For Regeneron, the deal secures a powerful commercial partner while allowing it to retain a significant role in development and a large share of future profits.
AdThe agreement covers several assets at different stages:
- REGN20423: The first drug is already in an early-stage clinical study for atopic dermatitis.
- Three other medicines: These are in earlier stages of development, with human testing anticipated to begin in 2027.
- Lunsekimig: Regeneron will have an option to add Sanofi’s experimental drug for chronic obstructive pulmonary disease (COPD) to the partnership after it completes late-stage testing.
Existing Partnership Unchanged
The companies confirmed that their existing, highly successful agreement for Dupixent will remain unchanged. Dupixent treats a range of inflammatory conditions and is a major revenue driver for Sanofi. As part of the new deal, the firms also settled a previous legal dispute, though no further details on the settlement were provided.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.